Combination therapies for the treatment of amyotrophic lateral sclerosis and related disorders

A method of treating or slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a first compound and a second compound,

• wherein
• the disease or condition is a neuron inflammation condition;
• and
• the first compound and the second compound are independently
• (a) a compound having formula (I):
• wherein
• X is halide, hydroxyl, or OCO(C1-8alkyl);
• Y is CO2R1 or CH2OR2;
• R1 is Li, Na, K, H, C1-4alkyl, or —CH2CO2(C1-5alkyl);
• and
• R2 is H or —C(O)(C1-4alkyl),
• or pharmaceutically acceptable salts thereof, or
• (b) selected from bitolterol, fenoterol, isoprenaline, levosalbutamol, orciprenaline, pirbuterol, procaterol, ritodrine, salbutamol, terbutaline, arformoterol, bambuterol, clenbuterol, formoterol, salmeterol, abediterol, carmoterol, indacaterol, olodaterol, vilanterol, nedocromil, ketotifen, olopatadine, omalizumab, quercetine, mepolizumab, azelastine, and methylxanthines pemirolast, olopataidne, alfatoxin G1, alfatoxin B1, alfatoxin M1, deoxynivalenol, zearalenone, ochratoxin A, fumonisin B1, hydrolyzed fumonisin B1, patulin, and ergotamine;
• or
• (c) edaravone or riluzole;
• or
• (d) selected from:
• or pharmaceutically acceptable salts thereof;
• or
• (e) a non-steroidal anti-inflammatory drug (NSAID);
• or
• (f) an anti-inflammatory peptide;
• and
• the first compound and the second compound, taken together, are therapeutically effective.